Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03642847 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT03642847 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 104 participants.
The verdict
NCT03642847, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
This Phase 1b will describe the safety and immunogenicity of 2 multivalent pneumococcal conjugate vaccine formulations in healthy Japanese adults in the United States.
Interventions
- BIOLOGICAL Prevnar 13
- BIOLOGICAL multivalent pneumococcal conjugate formulation 1
- BIOLOGICAL multivalent pneumococcal conjugate formulation 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2018-08-29 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03642847
The ClinicalTrials.gov registry entry for NCT03642847 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prevnar 13 is the first listed.
NCT03642847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03642847 about?
NCT03642847 is a clinical study titled "Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age". This Phase 1b will describe the safety and immunogenicity of 2 multivalent pneumococcal conjugate vaccine formulations in healthy Japanese adults in the United States.
What is the current status of trial NCT03642847?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2018-08-29. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03642847?
The interventions under investigation include: Prevnar 13 (BIOLOGICAL), multivalent pneumococcal conjugate formulation 1 (BIOLOGICAL), multivalent pneumococcal conjugate formulation 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03642847?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.